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Abstract
Background: Insulin pump therapy (IPT) is a technological advancement that has been 
developed to help people manage Type 1 diabetes (T1D). However, ways of managing 
diabetes requiring the implementation of health technologies bring new complexities 
and a need to understand the factors which enable people with T1D to incorporate a 
novel device. This new comprehension could provide an exemplar for people with 
long- term conditions to incorporate new technologies more generally.
Objective: To determine what influences the incorporation, adaptation and use of IPT 
into the everyday lives of people living with diabetes.
Design: Critical interpretive synthesis (CIS) using systematic searches undertaken in 7 
electronic databases of literature, published 2008 onwards.
Results: A total of 4998 titles were identified, 274 abstracts reviewed, 39 full articles 
retrieved and 22 papers selected for analysis. Three themes emerged which were of 
relevance to the introduction and use of IPT; Tensions between expectations and ex-
periences in adoption and early adaptation; Negotiation of responsibility and access-
ing support; Reflexivity, active experimentation and feedback.
Conclusions: This CIS builds on earlier reviews on lived experiences of IPT. Novel in-
sights are offered through examination of the experiences of pump users from children 
through to adults, their families and health- care professionals. Expectations of what the 
device can do to improve self- management impacts on the early stages of adoption as 
the reality of the technology requires substantial thought and action. Areas for interven-
tion to improve IPT incorporation include establishing who is responsible for manage-
ment tasks of the device and enabling navigation to further means of support and 
resources.
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1  | INTRODUCTION
Over 4 million people live with diabetes in the UK, and Type 1 dia-
betes (T1D) accounts for about 10% of that population.1 Continuous 
subcutaneous insulin infusion (CSII), insulin pump therapy, is a techno-
logical advancement used to support people with T1D manage their 
diabetes optimally. It is associated with psychosocial benefits (quality 
of life—QoL)2–16 and improved biomedical outcomes.2,4,8,10,12,14,17–41 
Historically, new ways of managing diabetes through implementing new 
health innovations have brought new complexities and are of particular 
relevance to CSII, which is more technologically advanced than previous 
modes of insulin delivery. Understanding the impact of these advance-
ments is an important avenue for exploration in providing a model of 
how people incorporate new and complex health tools which ostensibly 
provide much needed flexibility and choice in how people living with a 
long- term condition(s) can self- manage. The purpose of this review is to 
analyse existing literature about the processes of adoption, adaptation 
and embedding of a new physical health innovation (CSII) in the lives of 
people with T1D and the resources and support that enable this (Box 1).
Optimal self- care practices of people living with T1D constitutes a 
demanding and multifaceted regimen42 including monitoring and con-
trolling blood glucose levels, which are subject to extreme fluctuations, 
and risk of complications (Box 2).43–45 While multiple daily insulin injec-
tions (MDI) remain the main delivery method of insulin therapy glob-
ally,46 both MDI and CSII are recommended.38,47,48 However, the focus 
of insulin delivery is shifting towards the latter as a method considered 
more physiologically representative of a fully functioning pancreas.49,50 
CSII has been shown to yield particular benefits over MDI,16,29,38,51,52 
for example, lower cardiovascular mortality,53 higher treatment satisfac-
tion54 and improved glucose control.47 In 2008, the National Institute 
for Health and Clinical Excellence (NICE) recommended CSII for people 
with T1D whose glucose levels were not well controlled by MDI.38 This 
has been estimated to apply to 15%- 20% of adults living with T1D in 
the UK,55 compared to 6% currently utilizing CSII.56
Two reviews of CSII in 2003 and 2009 found that while CSII im-
proves glycaemic control, few studies have robustly assessed psy-
chosocial aspects of using insulin pumps.22,27 The latter is likely 
to be pertinent to assess given that CSII requirements are likely to 
constitute an added burden for people, particularly in the initial stages 
of adoption.22 A review by Barnard et al in 200757 established that 
studies, which do measure psychosocial aspects of CSII, were charac-
terized by; variable methodology and psychosocial constructs, small 
sample sizes, a focus on one particular patient group, or were dated 
(the devices have since become smaller, more accurate and more 
widespread). While understanding psychosocial outcomes is relevant 
to assessing the impact of CSII on well- being,22,27 it is important to 
explore the factors that may promote or inhibit its adoption and em-
bedding as a self- management strategy for T1D. Thus, exploration of 
existing evidence is needed to illuminate the processes and outcomes 
by which CSII becomes part of the management of diabetes.
This review is designed to build on earlier reviews by providing a 
current and in- depth exploration of user experience, and those inte-
grally involved in or impacting on this experience (i.e parents/caregiv-
ers/health- care professionals [HCPs]). The aim is to offer enhanced 
understanding of mechanisms that shape the incorporation, adaptation 
and use of CSII into the everyday lives of people living with diabetes, 
and establish what support and resources are needed to enable this.
2  | METHODS
2.1 | Study design
Critical interpretative synthesis (CIS) was used to identify domains 
from the literature that are key to successfully incorporating CSII. CIS 
is an exploratory method of reviewing literature, focused on prioritiz-
ing generation of theory in synthesizing findings. CIS allowed us to 
pragmatically explore the range of data and understand factors which 
may enable someone to incorporate an insulin pump into their eve-
ryday lives. The review had 3 stages: (i) Systematic search, (ii) Critical 
appraisal and (iii) Synthesis.
2.2 | Identifying relevant studies
A search strategy was developed incorporating the 3 main research 
aims: T1D (population); CSII (intervention); and terms relating to the 
psychosocial outcomes of the studies searched, using the PICOS 
Box 1 
Insulin pumps are electronic devices, about the size of a pager, which drip feed rapid- acting insulin via a fine cannula implanted into subcu-
taneous tissue continually throughout the day (called a basal dose).47 This device must therefore be worn constantly. The user then self- 
administers, as required, extra shots of insulin (called bolus doses) to match their intake of glucose (carbohydrates) throughout the day. These 
extra doses of insulin can be much more specific (and minute) at delivering insulin than traditional insulin injections. This apparatus also in-
tegrates what is called a “bolus calculator/advisor/wizard,” which recommend an appropriate (and usually personalised) insulin dose to the 
user.
K E Y W O R D S
critical interpretive synthesis, insulin pumps, new technology, psychosocial, social support 
networks, Type 1 diabetes
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model (Table 1). Different combinations of terms for each component 
were searched for (including relevant acronyms and truncations), to 
maximize capture of relevant literature.58 A systematic search of stud-
ies reporting users of pumps/HCP or significant other experiences of 
living with CSII was conducted using a range of databases: AMED; 
CINAHL; EMBASE; MEDLINE; PsycINFO; Cochrane database; Web 
of Science. An academic librarian and 3 other researchers (AR, MB 
and MCP) provided feedback on development of the search strategy 
and its results.
2.3 | Study selection and appraisal
Inclusion/exclusion (Table 2) and eligibility criteria (Table 3) 
were established using the PICOS approach. Initially, search cri-
teria did not exclude studies based on publication date; however, 
early searches indicated that the (most recent) changes to NICE 
guidelines (2008)38 considerably widened pump uptake, and 
consequently technological advancement and research of this 
device. We therefore restricted our inclusion criteria to studies 
published 2008 onwards. However, some of the included papers 
were retrospective, and involved interviewing people who had 
been using CSII for 5+ years. These papers were included on the 
basis that they provided useful background and contextual in-
formation, and some of the barriers and facilitators to adoption 
and embedding of CSII remain relevant. Although quantitative 
evidence was also reviewed, these papers were not included in 
the final analysis because they did not sufficiently explore lived 
experiences of CSII.
Duplicate papers were removed before screening (Figure 1). 
Titles and abstracts were screened by CR and a second reviewer 
from the team (split between MB, AR, AK and IV). Disagreements 
about inclusion were resolved at the title screen stage by third re-
view (IV) and through discussion between CR, AK and AR at the 
abstract stage. Thirty- nine full- text articles were reviewed by both 
CR and AR, and one further article was identified through screening 
the reference lists of the full- text articles. After exclusions, quality 
appraisal was performed by CR and AR using guidance from Dixon- 
Woods et al.101 Included papers were deemed as mostly good 
quality based on this guidance, except for 2 which were included 
because of theoretical relevance.59 The final literature search was 
run in March 2017.
2.4 | Data extraction and synthesis
Key information was extracted from papers using a data extrac-
tion form including (i) background information about each paper, 
(ii) key findings and themes identified by authors, (iii) references 
Box 2 
“The [NICE] guidance states that continuous subcutaneous insulin infusion (CSII) or ‘insulin pump’ therapy is recommended as a treatment 
option for adults and children 12 years and over with Type 1 diabetes mellitus if:
• attempts to reach target haemoglobin A1c (HbA1c) levels with multiple daily injections result in the person having ‘disabling hypoglycae-
mia’, or
• HbA1c levels have remained high (69 mmol (8.5%) or above) with multiple daily injections (including using long-acting insulin analogues if 
appropriate) despite the person and/or their carer carefully trying to manage their diabetes
CSII therapy is not recommended as treatment for people with Type 2 diabetes mellitus.”102
TABLE  1 Search strategy key terms
Number Term OR/AND
S1 “insulin pump” OR
“continuous subcutaneous 
insulin infusion”
“CSII”
“closed- loop glucose control”
“Open- loop glucose control”
S2 Habituation* OR
Psychophysiologic*
Adaptation*
“Quality of Life”
“Normalisation”
“Normalization”
Incorporat*
Integrat*
Impact*
Perception*
Experience*
Opinion*
Attitude*
“Social- support”
Cope*
Coping*
Burden*
“living with”
“psychosocial”
Psychol*
“Social- functioning”
S3 S1, S2 AND
S4 S3 Limited to English
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by authors in terms of implications and/or suggestions for im-
provement for incorporation of the device, (iv) critical interpre-
tations by reviewers of key themes for CSII incorporation and (v) 
how/whether social support was defined/discussed. The data 
in the review constituted the main themes reported in each of 
the individual studies.60 Each paper was analysed in considera-
tion of themes identified, after which the papers were system-
atically compared. CR reviewed full papers, and review findings 
were then discussed and refined with AR and IV in an iterative 
process. Where more than one paper contributed to a single 
theme, identifying numbers from the studies were noted at the 
end of each theme. This enabled relationships across the studies 
to be identified and provided the basis for a broader explanatory 
framework.
3  | RESULTS
Twenty- two studies were identified which described the experi-
ences of CSII from the perspectives of children/adolescents/young 
adult pump users (9) (Participants n = 251), adult pump users (8) 
(Participants n = 143), HCPs (4) (Participants n = 61) and/or parents 
of pump users (7) (Participants n = 266). Eighteen of the papers were 
qualitative, and 4 used mixed methods. Contextual data from each of 
the papers are presented in Table 4.
From the data analysis, 3 themes of relevance emerged: “Tensions 
between expectations and experiences in adoption and early adapta-
tion; Negotiating responsibility and accessing support from health- care 
professionals and wider networks; and Reflexivity, active experimen-
tation and feedback”.
3.1 | Tensions between expectations and 
experiences in adoption and early adaptation
Polarization between expectations and experiences of users in learn-
ing to live with the technology was reported as common in the early 
stages of adoption. Prominent in the narratives was the device al-
lowing for “increased flexibility” but accompanied by descriptions of 
on- going disruption in daily activities, and needs for adjustment when 
initiating this type of insulin therapy.61–63
There were differences in people’s initial expectations. Where 
some saw the pump as a panacea for insulin delivery, others simply 
saw the device as a tool, which incrementally improved existing ef-
forts at diabetes- related daily management by making subtle but use-
ful adjustments.
TABLE  2 Selection criteria determined using the PICOS model
Selection criteria Inclusion Exclusion
Population • People with Type 1 or Type 2 diabetes
• People who have an insulin pump
• People who are considering using CSII
• Research from the perspective of health-care profession-
als/carers/relatives
• Non-routine use of CSII (such as use specifically in 
pregnancy or in hospitals)
Intervention(s) • Routine use of CSII • No focus/data on experience of living with the pump
• Purely biomedical focus on the insulin pump
• Research focused on continuous glucose monitoring 
(CGM)
Comparison(s) [none] [none]
Outcome(s) [none] [none]
Study design(s) • Research protocols
• Qualitative
• Observational
• Methodological (including development work)
• Review
• Mixed methods
• Purely quantitative
Publication type(s) • Peer-reviewed original research article or review
• Databases and registers of on-going studies
• Patent
• Commentary
• Editorial
Publication year(s) • >2008
Language(s) • English
TABLE  3 Eligibility criteria for literature identified in the search
Inclusion Studies examining some form of psychosocial aspect 
of living with CSII
Peer- reviewed original research or review
Studies published from 2008 to March 2017
Research using qualitative or mixed methods, as well 
as literature reviews, review papers, reports, 
conference papers
Papers examining routine use of the pump
Exclusion Abstracts that do not have a full- text article available
Papers not written in English
Papers with a purely biomedical or quantitative focus
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In the way, simple. Really I think it is in the way and the 
fact that it didn’t meet up to the expectations that I per-
haps thought it would in overall control.
(Female who discontinued CSII)64
I have a very stationary job but I am fairly active at the 
weekends and then I can sometimes adjust to a temporary 
basal rate, or change the programme. I have a basal pro-
gramme that is lower.
(Female, aged 52 years)61
This initial expectation (and potential contradiction) was 
seen as important to address by all parties (users/parents/
HCPs)21,61–66 and perceptions of what the pump could do 
shaped subsequent expectations of the amount and nature 
of work required to master living with this new device.63,67,68 
Reasons given by people with T1D for wanting to move to 
CSII from MDI included pursuit of greater stability and con-
trol over blood sugar levels, and desire for a more flexible life-
style.11,69,70 Most users indicated that the new equipment made 
self- management easier in terms of work required to balance 
glucose levels, enabling them greater flexibility in, for example; 
when/where/how they chose to eat; and undertaking sponta-
neous activities.11,21,61–63,65–67,69,71
It just gets better and better; the transition from syringes 
to pump was painless. I think it is much easier to have the 
pump than all those syringes.
(Male, aged 25 years)69
By comparison, MDI was described by some as an insensitive ap-
proach to physiologically imitating insulin production, with inability to 
adjust levels of insulin in the body for up to 24 hours;
The pump allows me to obtain tight control of my blood 
glucose by administering very small amounts of insulin…
which cannot be done with insulin injections…this pre-
vents me having to have a higher basal rate…which leads 
to more hypos because it is too much insulin for me.
(Gender unknown, aged 25 years)68
However, improved self- management and “flexibility” sat in ten-
sion with increased expectations to learn new “work”; new skills and 
adopt new practices associated with a more complex piece of technol-
ogy.11,52,61,63–65,69,70,72–74 Parents reported “putting their life on hold”52 
while integrating the new tool into management of their child’s diabetes. 
Acquiring new skills relating to use and monitoring of the device was 
seen as tedious, challenging11,52,63 and burdensome with respect to the 
complexity and frequency of some tasks.63,74
Considering where and how to wear this contraption on the body 
also illuminated constraints to “flexibility,” while a potential disso-
nance seemed to occur between expectations that insulin manage-
ment is automatic and simplified with the reality of the new machine 
requiring substantial thought and action. Feelings of vulnerabil-
ity were also described when there was an overwhelming need to 
prepare for potential failures in this new apparatus.61,64,75 This was 
often reported as illness- burden, particularly in studies represent-
ing the views of adults and parents, and during the early stages of 
adoption.52,61,64,65,69,74,75
F IGURE  1 PRISMA flow diagram of identified articles
Records identified through 
database searching 
(n = 4998)
Patents removed (n = 5)
Articles published <2008 removed 
(n = 898)
Duplicates removed (n = 2145)
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n
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Ineligible articles removed
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Full-text articles of relevant 
abstracts read (n = 41)
Records identified through 
reference mining (n = 1)
Studies included in critical 
synthesis (n = 22)
Records identified through 
search rerun (Mar ’17) (n = 1)
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In addition to new work, the device also introduced new inflexibilities. 
Typical daily experiences of CSII were described in dichotomized terms 
as representing both a shackle and lifeline.61 For many, the pump was 
experienced as constraining because it interfered with day- to- day life, 
due to the increased visibility necessitating further work to discretely at-
tach this piece of equipment to the body, and/or the status attributed to 
a permanent appendage to be worn 24/7.52,61,62,64,65,69,70,74,76 Physical 
restrictions were also imposed, which were caused by the bulky nature 
of the tool and its connecting tubes and alarms.
As a woman, I like tight skirts and dresses, I can’t wear that 
anymore. I have to choose clothes based on the pump.
(Female 43 years)69
Women expressed more concern than men about body image and so-
cial acceptance in terms of the visibility and concealment of the pump.64,69,76 
Parents were less concerned about practicalities of wearing the device, and 
more with the reliance and safety of the technology.11,52,65,73,75 These dis-
advantages illuminate discrepancies between expectations and realities 
of introducing a new health contraption, and a variety of experiences and 
perspectives on its adoption. Different demands in daily activities, and in 
user’s preferences and priorities, mean that everyday contexts in which the 
device may be accommodated is variable, and that there are a range of 
“trade- offs” between the limitations and advantages of CSII.
There were descriptions of persistent aloneness in trying to be 
“normal,” and trying to hide the equipment from others to achieve this. 
Many users of CSII expressed feelings of being different from peers, 
yet wanting to be and feel “normal”.61,62,66,70,74,76,77
When you take it out [the pump] you feel like you’re expos-
ing something about yourself for people to, sort of, either, 
sort of, judge that it’s good or bad, in a way, and then I 
more, sort of, fear someone’s reaction.
(Female, age unknown)76
Living with diabetes was described as a constant struggle, and the pro-
cess of self- management as isolating and lonely,70 especially when there 
was a potential for prying or judgement from others.62,66,69,70,72,73,76–78 
Intimate relations were also discussed with reference to the inevitable 
awkwardness in explaining the device to a sexual partner, or the con-
traption getting in the way.61,62,64,69,76 While most users expressed being 
open to others, some preferred not to expose their diabetes diagnosis 
or means of insulin delivery to strangers.61,62,64,69–71,76–78 However, 
contemporary popular interest in innovation was thought to assist in ex-
plaining the condition to others, using the apparatus (a relatively familiar 
looking object) as opposed to injections (MDI).52,61–63,69,70
3.2 | Negotiating responsibility and accessing 
support from health- care professionals and 
wider networks
This second theme highlights the ensuing need for emotional and 
practical assistance, and understanding of who is responsible for the 
management tasks relating to the pump, during the initial phase of 
adoption.
How individuals incorporate the device and undertake activities 
relies, to an extent, on external influences, encompassing a range of 
social and health- care support- related relationships. Users of CSII ar-
ticulated how social support provided additional assistance, and how a 
network of support enabled the work of self- management to be shared 
out.62,63,67,71 HCPs also echoed the importance of on- going multifac-
eted, holistic and tailored expertise in facilitating CSII use.66,79 However, 
not all social interactions were viewed as beneficial to self- management.
In the main, facilitation and encouragement from family mem-
bers and HCPs in adapting to and understanding the mechanisms of 
the device were considered helpful by those living with this tool.72,78 
Mastering CSII, from the user’s point of view, was described as easier 
when there was trust and assistance from HCPs, which was tailored 
and holistic.61,70
I don’t want my blood sugars to be high all the time or low 
all the time…But when [the HCP] adjusts stuff without 
looking at what’s actually going on or listening, it’s just 
kind of pointless.
(Sex unknown, young adult, exact age unknown)70
The complexity of the equipment could make users feel vulnerable in 
terms of needing backing to programme and manage its more advanced 
features.61,69 Complex tasks included understanding how insulin is ad-
ministered, and sharing practical tips for discrete/un- invasive placement 
on the body (from other users or HCPs). Advocated assistance included 
provision of psychological support in clinics and play therapy for younger 
children. Aids to assist with subcutaneous cannula insertion, simplify-
ing the process and easing pain, or testing a saline pump to experience 
how it feels to be attached to the device before implementation were 
also advised,73 as well as more information and interaction to set up the 
machine.69,71,79 However, too much information at initiation could be 
unhelpful. Not seeking or having any on- going support or information 
about the equipment proved to be detrimental to incorporation.64,71,79
Assistance and information from others in a non- clinical setting 
was identified as relevant. Insulin pump users described wanting to 
learn about the device and find ways to fit it into their lives through 
learning from peers (i.e people who actually have experience of living 
with T1D).70,72
We’re like, ‘How’s your blood sugar?’… “We’ll joke about it 
[blood sugar levels]. It’s…reassuring, that other people are 
going through it too, you know. So you don’t feel as weird…
You feel kind of normal.
(Female, young adult, exact age unknown)70
Interactions with peers offered the prospect of support, shared 
learnings and practical solutions for day- to- day problems.11,62,68,70,72 
Connecting with others through face- to- face contact or through blogs 
was considered valuable.70 Similarly, meeting other families was valued,73 
where parents with some shared responsibility for managing this machine 
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 c
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 p
er
io
d 
th
er
e 
ar
e 
sig
ni
fic
an
t 
im
pr
ov
em
en
ts
 in
 Q
oL
 fo
r u
se
rs
. T
he
re
 is
 a
 c
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 m
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re
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 c
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n 
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 c
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 c
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r t
he
 p
um
p,
 b
od
y 
an
d 
he
al
th
; a
nd
 c
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 g
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at
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 p
ro
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 p
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 d
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t f
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re
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r m
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 b
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 m
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 p
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f t
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 o
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 b
et
w
ee
n 
ad
ol
es
ce
nt
s 
an
d 
th
ei
r p
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 b
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m
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 d
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 d
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is,
 fr
om
 
th
e 
ad
ol
es
ce
nt
s’ 
po
in
t o
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f t
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 m
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 c
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 c
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 m
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at
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pe
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r p
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 p
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t o
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 d
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 d
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pa
ct
 o
n 
th
e 
Q
oL
 fr
om
 g
re
at
er
 fl
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; d
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 d
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 d
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f p
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 re
ce
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 c
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 p
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ra
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f f
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r p
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 d
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ag
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em
e 
re
ve
al
ed
 th
at
 in
su
lin
 p
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ra
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 b
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 re
lie
ve
d;
 a
nd
 
st
ig
m
at
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f f
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 p
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 fl
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r d
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 c
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 b
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 re
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; l
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 re
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 o
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 d
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r f
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 b
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 m
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 C
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 p
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 c
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 d
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 p
at
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 m
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re
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 c
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r p
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 p
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 m
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s
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: r
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f m
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 d
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 d
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 c
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 d
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 p
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 d
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f c
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 b
ei
ng
 tr
ea
te
d 
w
ith
 C
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 p
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 d
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f l
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f l
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 d
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 d
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 c
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 b
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re
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 c
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also reported on the initial burden.11,52,65 Valued elements of meeting oth-
ers included; sharing the training experience, meeting others in the same 
situation and a relaxed atmosphere, which facilitated troubleshooting.
However, accessing aid, whether from peers, family members or 
HCPs was influenced by the level of responsibility taken, or desired, 
from the user.
It’s starting to hit me now… I don’t realize that the diabetes 
is damaging [my body] … It [having the pump] was just kind 
of a wake- up call… is my responsibility … not my mom’s.
(Female, young adult, exact age unknown)70
The level of responsibility is also seen to vary between age groups, 
from younger children needing more intensive parental assistance to 
adults wanting to feel a full sense of control over their diabetes, and incre-
mental changes in desired responsibility in between.61,62,64,65,67,70,72,77,78
There are also times when the need for support varies (e.g in times 
of sickness). The establishment of distribution and transfer of respon-
sibility from parents to children, adolescents and young adults was 
discussed. Parents often hold most of the responsibility of diabetes 
management for children, which is gradually handed over, to varying 
effect.52,62,67,70,71,73,77
But now, in the autumn she missed a little bit again [of 
insulin doses]. Then I realized that it’s not possible to leave 
the responsibility to her so much, because it didn’t work, 
she forgot doses and such.
(Mother)67
A hindrance to this transfer of responsibility could be parental fear of 
the ability of the child to self- manage and so the parent may be reluctant 
to surrender responsibility. Parents were quoted as desiring education 
and assistance themselves.65,67
3.3 | Reflexivity, active experimentation and feedback
This theme focuses on challenges faced by new pump users, and the 
process of the integration and normalization of the device. The term 
“reflexivity” here refers to how experiences that interrupt what is nor-
malized and/or habitual for individuals are encountered and understood 
consciously (i.e reflexively), and the implications that this has for how 
people then act and incorporate the new apparatus into their everyday 
lives.
Normalization of this piece of equipment as a new practice is a 
process of gradual acceptance and assimilation. Some respondents 
described how the device felt like a tattoo, an appendage, or an ex-
tension of self after the initial period of getting to grips with the new 
contraption, requiring a journey of reflection, active experimentation 
and feedback.62,65,70,76
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telling someone I got a new tattoo… It’s [the pump] just 
a part of me.
(Male, young adult, exact age unknown)70
Adoption was predicted on a demand that the user trust the 
machine to perform its functions safely.62,64,75,78 In addition to ad-
justing to the initial complexities, fear that the apparatus would do 
something that the user does not want it to, or not wanting to give 
up control suggests psychological adjustments alongside other prac-
tical adjustments.
At night I can’t help think that if the buttons pressed or 
… even in the day if you knock it [the pump] or something 
goes in or too much, you haven’t got full control over what 
you are putting in your body really so that was part of it 
as well
(Female who discontinued CSII)64
Over time, the initial stress and vulnerability created by dependence 
on a machine gave way to feelings of autonomy when the technology 
was mastered.61,64–66,69,70,73–75
You have to be a bit knowledgeable as well and you have 
to learn about the pump yourself very carefully… It’s a case 
of having the courage to try the different functions of the 
pump, so you know what to do if something goes wrong.
(Female, aged 54 years)61
Users of CSII reported the need for a period of adjustment 
to feel comfortable with being attached to a machine 24 hours a 
day.61,62,64,67,69,70,72,76–78
The visibility of the device created a sense of heightened aware-
ness of one’s body and as a result a greater need for assistance to 
adapt and find ways to comfortably situate the machine at the point 
of introduction.52,62,69,73 Through technical control of the apparatus, 
and resulting stabilized blood glucose levels, greater personal control 
was realized.69,78 A common depiction of incorporation involved the 
need to gain motivation and confidence to adapt it.21,52,61,65,68–70,78 
For example, a parent of a young child using CSII commented on how 
longer term benefits were predicated on performing necessary work 
during the adoption phase;
You take care of it [diabetes] yourself. It’s freedom with re-
sponsibility. That demands courage.
(Parent)65
4  | DISCUSSION
This review suggests a period of adjustment and experience that 
emerges over time, and a process of incorporation that changes from 
the point of anticipation (pre- CSII) through to adoption. This process 
is accompanied by having to navigate and be responsive to a range 
of contingent bodily sensations and technological demands that were 
unexpected at the outset. There is an initial liminality associated with 
use of the pump as a foreign object, and upon introduction users feel 
that they are on the edge of something new. People living with diabe-
tes who adopt CSII do so with existing experiential knowledge of their 
condition; as such the process of adjustment necessary to embed this 
technology into everyday life includes integration of new knowledge 
about management combined with their existing understandings.
Initial expectations shape both the type and amount of work the 
person subsequently puts in to adopting and integrating the device 
into his/her daily life. Negotiation of responsibility and access to per-
sonalized information, support and resources can affect how well s/he 
is able to incorporate CSII. What follows is a need to engage in active 
experimentation, in which the user reflects on his/her experience and 
feeds that back into use of the appliance, adapting it to his/her needs. 
This can also be facilitated through negotiation of the assistance avail-
able to him/her (e.g shared experiences of other users of CSII, feed-
back from HCPs). The more the new pump user becomes accustomed 
to the tool, its physical presence and the greater the degree of aid 
available to him/herself and his/her families/significant others, the 
easier it can be incorporated.
This review suggests a qualitative difference between using MDI 
and CSII which centres on experiencing metabolic improvements, 
but also to feelings of ease, personal control and confidence in 
using and habituating to more complex technology. The apparatus 
evokes feelings of technological advancement and flexibility, and 
so high expectations of the device’s potential are engendered. The 
previous method of insulin delivery required needles, a very physical 
but singular interaction, whereas this machine is integrated into the 
body 24/7. This process can make users much more aware of their 
body image and appearance. Additionally, using CSII introduces new 
types of work, the completion and normalization of which requires 
acquiring new skills and renegotiating relations within personal 
communities.
The review also suggests that if a new user of CSII has no access 
to additional support or resources, then their ability to incorporate the 
new appliance will be hindered. It has been found that effective di-
abetes medical care and self- management is enriched by improving 
access to specialist and on- going diabetes HCPs.80–82 However, HCPs 
providing care for patients with diabetes do not currently receive post-
graduate training for the relief or assessment of educational, medi-
cal, emotional or psychological aspects of diabetes.83 Other means 
to supplement this support are therefore vital. Many aspects of self- 
management are more achievable through working with others, by al-
lowing knowledge, skills and resources to be pooled.84,85
The, very recent (post- March 2017), Relative Effectiveness of 
Pumps Over MDI and Structured Education (REPOSE) trial,86 com-
pared CSII with MDI, with findings that resonate with this current 
review including pump expectations not being met but experienc-
ing; increased discretion, flexibility and spontaneity (especially with 
food or exercise). The report, however, focused on improvements in 
diabetes self- management due to structured education and on- going 
support. Studies considered here indicate that there is a potentially 
     |  13REIDY Et al.
stressful element in introducing a new and complex technology into 
someone’s life. The role of others in accessing assistance could be a 
future avenue to explore. What we do know is that social networks 
and good social support are associated with better functioning, fewer 
psychosocial problems and improved self- management in people with 
diabetes in general.87,88 Social networks can provide emotional and/or 
practical aid as well as facilitating a means to mobilize, negotiate, me-
diate and access further means of assistance.89–92 A supportive social 
network is known to have a “buffering” effect in situations eliciting 
stress (such as the introduction of a complex new technology),93,94 
but the impact of social networks amongst people living with CSII is 
not well, or reliably, documented.95 When CSII is first introduced, the 
level of responsibility taken for pump management is as much as the 
user is willing to accept, and this varies. The desire for responsibility 
of self- management is thought to increase from childhood through to 
adulthood, and negotiation with caregivers is required to share out 
tasks. The findings in this synthesis not only resonate with and com-
pliment research on social networks in long- term conditions (outlined 
above), but also with studies examining shared responsibility between 
adolescents with T1D and their caregivers.96,97 While motivation to 
take responsibility for self- management is important,81,98 motivation 
is not all that is required, as people living with T1D may, for example, 
feel fatigued. Sharing responsibility for the work of managing the con-
dition can enable better self- management and improved health out-
comes through sharing the illness and CSII- related burden associated 
with the complexity, frequency and relentless nature of some self- 
management tasks.98,99 This is where a link to support and resources 
could prove crucial.
4.1 | Implications
These findings identify the types of beliefs that influence the 
adoption and diffusion of technologies. In terms of CSII, barriers 
to incorporation for the person with diabetes include the tension 
between the expectations of the device and the actual experience. 
For improved integration, early conversations are needed from 
HCPs about the likely period of disruption. Potential pump users 
have not been familiarized with the work that is going to be carried 
out, and they need time, resources and information to overcome 
this. HCPs and manufacturers of CSII need to be realistic with po-
tential users so that they can anticipate this work. Frank conversa-
tions about the limitations of the apparatus are necessary. People 
with diabetes need to be given the opportunity to build confidence 
about using this new appliance, and negotiations between children/
adolescents and their parents must be undertaken. Being prepared 
for the time required to work the contraption into their lives, as 
well as sensitivity to the inevitable variability between users could 
set realistic expectations. Harrison100 described how perceived as-
sistance from HCPs or peers formed an important aspect of patient 
satisfaction and should be considered for future interventions. In 
examining the social network that pump users have access to, and 
enabling them to tap into further (and on- going) means of support 
and resources, users of CSII could incorporate the apparatus more 
successfully.
4.2 | Limitations
A number of limitations must be acknowledged with respect to the 
present review. Firstly, the findings of the synthesis reflect the back-
ground and experiences of the reviewers, and as such are subjective. 
We acknowledge that the findings could have been different if con-
ducted by a different set of researchers, however, steps have been 
taken in line with guidance101 to ensure transparency in reporting on 
analytic processes which informed our analyses. Secondly, the papers 
included in the review incorporated a variety of methods, meaning 
that data quality was variable. The authors were sensitive to the qual-
ity of the methodology and did bear this in mind throughout the data 
analysis, and no concerns were raised with respect to the veracity of 
reporting or integrity of findings.
Thirdly, while men and women were, roughly, equally represented 
as participants in the papers reviewed (where these were reported; 
44% vs 56%), it appears that men were relatively underrepresented in 
the quotes given in the papers (15% vs 45%—with the remaining 40% 
of quotes being non- gender specific). Therefore, quotes offered in this 
synthesis of papers could potentially offer a pump adoption experi-
ence that is skewed towards female users. One possible contributor 
to this gender imbalance could be that more women expressed fears 
and concerns relating to body image and social acceptance than male 
participants.
Fourthly, reporting on demographic composition of study sam-
ples was not consistent across the papers reviewed. For example, 
not all studies disclosed the mean/median age21,62,64–66,68,76,78,79 
or range64,72,74 of their participants. For those that did, the range 
was from 5 to 80, and of HCPs, the range of years in practice was 
2.5- 45. The papers included a range of ages (children, adolescents, 
young adults, adults) and perspective (users of CSII, parents, HCPs), 
which offered an array of insights. However, saturation was not 
reached for any demographic group or perspective. Future studies 
may therefore look to explore comparatively the experiences of sub-
groups within the population of CSII adoptees and their families/
significant others.
5  | CONCLUSION
This review makes several original contributions to the knowledge 
base relating to experiences of pump users adoption and use; (i) 
investigation of recent studies not included in previous reviews of 
CSII device adoption; (ii) synthesis of lived experiences of users of 
various ages, in greater depth; (iii) synthesis of perspectives from 
parents and HCPs. To our knowledge, this review also represents 
the first to explore, qualitatively and pragmatically, the process 
of incorporating a new technology, worn 24/7, in a long- term 
condition.
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